FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2729521026> ?p ?o ?g. }

• W2729521026 endingPage "1211" @default.
• W2729521026 startingPage "1201" @default.
• W2729521026 abstract "•Metabolic syndrome (MS) did not affect progression of atherosclerotic cardiovascular disease (ASCVD). •The number of MS components did not predict cardiovascular outcomes in established ASCVD. •Diabetes mellitus but not MS was associated with higher events in patients with established ASCVD. Background Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. Objectives This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. Methods We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. Results The composite primary end point of CV events occurred in 15.1% of patients without MS vs 13.8%, 16.9%, and 16.8% of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P = .55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. Conclusions The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components. Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. The composite primary end point of CV events occurred in 15.1% of patients without MS vs 13.8%, 16.9%, and 16.8% of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P = .55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components." @default.
• W2729521026 created "2017-07-14" @default.
• W2729521026 creator A5011241982 @default.
• W2729521026 creator A5015234811 @default.
• W2729521026 creator A5032669172 @default.
• W2729521026 creator A5036558176 @default.
• W2729521026 creator A5052922735 @default.
• W2729521026 creator A5064084589 @default.
• W2729521026 creator A5069006768 @default.
• W2729521026 creator A5077115363 @default.
• W2729521026 creator A5081076066 @default.
• W2729521026 creator A5082012532 @default.
• W2729521026 creator A5089190791 @default.
• W2729521026 creator A5089418361 @default.
• W2729521026 creator A5089480092 @default.
• W2729521026 date "2017-09-01" @default.
• W2729521026 modified "2023-10-18" @default.
• W2729521026 title "Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial" @default.
• W2729521026 cites W1579491283 @default.
• W2729521026 cites W1859162852 @default.
• W2729521026 cites W1983273787 @default.
• W2729521026 cites W2016308382 @default.
• W2729521026 cites W2019071303 @default.
• W2729521026 cites W2029935130 @default.
• W2729521026 cites W2039428219 @default.
• W2729521026 cites W2108362443 @default.
• W2729521026 cites W2123201750 @default.
• W2729521026 cites W2123289485 @default.
• W2729521026 cites W2160234571 @default.
• W2729521026 cites W2165605025 @default.
• W2729521026 cites W2319057797 @default.
• W2729521026 cites W2324454784 @default.
• W2729521026 cites W2410405995 @default.
• W2729521026 cites W2607031541 @default.
• W2729521026 cites W4230870013 @default.
• W2729521026 cites W4236673002 @default.
• W2729521026 cites W4244540230 @default.
• W2729521026 cites W4318598273 @default.
• W2729521026 doi "https://doi.org/10.1016/j.jacl.2017.06.017" @default.
• W2729521026 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5612889" @default.
• W2729521026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28807460" @default.
• W2729521026 hasPublicationYear "2017" @default.
• W2729521026 type Work @default.
• W2729521026 sameAs 2729521026 @default.
• W2729521026 citedByCount "12" @default.
• W2729521026 countsByYear W27295210262018 @default.
• W2729521026 countsByYear W27295210262019 @default.
• W2729521026 countsByYear W27295210262020 @default.
• W2729521026 countsByYear W27295210262021 @default.
• W2729521026 countsByYear W27295210262022 @default.
• W2729521026 countsByYear W27295210262023 @default.
• W2729521026 crossrefType "journal-article" @default.
• W2729521026 hasAuthorship W2729521026A5011241982 @default.
• W2729521026 hasAuthorship W2729521026A5015234811 @default.
• W2729521026 hasAuthorship W2729521026A5032669172 @default.
• W2729521026 hasAuthorship W2729521026A5036558176 @default.
• W2729521026 hasAuthorship W2729521026A5052922735 @default.
• W2729521026 hasAuthorship W2729521026A5064084589 @default.
• W2729521026 hasAuthorship W2729521026A5069006768 @default.
• W2729521026 hasAuthorship W2729521026A5077115363 @default.
• W2729521026 hasAuthorship W2729521026A5081076066 @default.
• W2729521026 hasAuthorship W2729521026A5082012532 @default.
• W2729521026 hasAuthorship W2729521026A5089190791 @default.
• W2729521026 hasAuthorship W2729521026A5089418361 @default.
• W2729521026 hasAuthorship W2729521026A5089480092 @default.
• W2729521026 hasBestOaLocation W27295210262 @default.
• W2729521026 hasConcept C126322002 @default.
• W2729521026 hasConcept C134018914 @default.
• W2729521026 hasConcept C142724271 @default.
• W2729521026 hasConcept C204787440 @default.
• W2729521026 hasConcept C207103383 @default.
• W2729521026 hasConcept C27081682 @default.
• W2729521026 hasConcept C2778096610 @default.
• W2729521026 hasConcept C2779134260 @default.
• W2729521026 hasConcept C2780092750 @default.
• W2729521026 hasConcept C2780578515 @default.
• W2729521026 hasConcept C2909478654 @default.
• W2729521026 hasConcept C44249647 @default.
• W2729521026 hasConcept C511355011 @default.
• W2729521026 hasConcept C555293320 @default.
• W2729521026 hasConcept C67761136 @default.
• W2729521026 hasConcept C71924100 @default.
• W2729521026 hasConceptScore W2729521026C126322002 @default.
• W2729521026 hasConceptScore W2729521026C134018914 @default.
• W2729521026 hasConceptScore W2729521026C142724271 @default.
• W2729521026 hasConceptScore W2729521026C204787440 @default.
• W2729521026 hasConceptScore W2729521026C207103383 @default.
• W2729521026 hasConceptScore W2729521026C27081682 @default.
• W2729521026 hasConceptScore W2729521026C2778096610 @default.
• W2729521026 hasConceptScore W2729521026C2779134260 @default.
• W2729521026 hasConceptScore W2729521026C2780092750 @default.
• W2729521026 hasConceptScore W2729521026C2780578515 @default.
• W2729521026 hasConceptScore W2729521026C2909478654 @default.
• W2729521026 hasConceptScore W2729521026C44249647 @default.
• W2729521026 hasConceptScore W2729521026C511355011 @default.
• W2729521026 hasConceptScore W2729521026C555293320 @default.
• W2729521026 hasConceptScore W2729521026C67761136 @default.
• W2729521026 hasConceptScore W2729521026C71924100 @default.

• next